The addition of platinum compounds to standard chemotherapy for breast cancer patients
Peter Schmid • 8 Sep 2016
Should polygenic risk scores be used to risk-stratify the use of PSA-screening in prostate cancer?
Andrew Vickers • 11 May 2022
Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBC
Benedetta Conte • 5 May 2022